Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Indication
Institution
Department
Principal Investigator
Protocol Title
TMU-JIRB No. Protocol Title Indication Institution Department Principal Investigator Contact
N202307012 An Open-Label multinational, multicenter study to evaluate the long-term safety, tolerability and efficacy of subcutaneous amlitelimab in adult participants with moderate to severe atopic dermatitis Atopic Dermatitis SHH Dermatology

Woan-Ruoh Lee

 02-6620-2589
N202312002 A Randomized, Double-Blind, Placebo-Controlled, Multi-Regional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy Lung Cancer SHH Pulmonary Medicine

Kang-Yun Lee

 02-6620-2589
N202401013 A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma Melanoma SHH Hematology and Oncology

Yao-Yu Hsieh

 02-6620-2589
N202402003 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN) Nephropathy SHH Nephrology

Mai-Szu Wu

 02-6620-2589
N202404021 A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors Solid tumors SHH Hematology and Oncology

Wei-Hong Cheng

 02-6620-2589
N202407071 A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic CD20-Conjugated Gamma Delta T-Cell therapy, in Adult Subjects with Relapsed/Refractory CD20 Expressing B-cell Malignancies B-cell Malignancies SHH Hematology and Oncology

Yao-Yu Hsieh

 02-6620-2589
N202408025 An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-Cell Malignancies B-Cell Malignancies SHH Hematology and Oncology

Yao-Yu Hsieh

 02-6620-2589
N202408028 A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC Non snall cell Lung Cancer (NSCLC) SHH Pulmonary Medicine/Sleep Clinic

Kang-Yun Lee

 02-6620-2589
N202409018 A Phase 3, Randomized, open-label Study of Nivolumab + RelatlimabFixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 expression of 1% to 49% Non snall cell Lung Cancer (NSCLC) SHH Pulmonary Medicine/Sleep Clinic

Kang-Yun Lee

 02-6620-2589
N202409020 A Phase 2/3, Multicenter, Open-label Trial to Evaluate the Long-term Safety, Tolerability, and Efficacy of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy Immunoglobulin A Nephropathy SHH Nephrology

YUNG-HO HSU

 02-6620-2589
1 2 3 4 5 6 / 6

TOP